sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
infecti
diseas
caus
sft
viru
sftsv
novel
bunyaviru
sftsv
first
isol
patient
present
fever
thrombocytopenia
leukocytopenia
multiorgan
dysfunct
china
subsequ
found
wide
distribut
southeast
asia
korea
japan
vietnam
sftsv
transmit
tick
also
domest
anim
companion
anim
human
case
fatal
rate
sft
high
develop
specif
effect
treatment
sft
requir
studi
potenti
antivir
drug
sftsspecif
therapi
conduct
exist
newli
discov
agent
vitro
vivo
ribavirin
favipiravir
promis
candid
anim
experi
retrospect
studi
demonstr
limit
efficaci
ribavirin
also
specul
ribavirin
would
effect
patient
viral
load
copiesml
favipiravir
show
higher
efficaci
ribavirin
sftsv
vitro
assay
greater
efficaci
anim
model
even
administr
day
viru
inocul
although
clinic
trial
evalu
efficaci
favipiravir
sft
patient
japan
underway
yet
confirm
drug
includ
hexachlorophen
calcium
channel
blocker
deoxycytidin
caffeic
acid
amodiaquin
interferon
also
evalu
inhibitori
efficaci
sftsv
among
calcium
channel
blocker
promis
addit
efficaci
vitro
vivo
retrospect
clinic
data
indic
nifedipin
one
calcium
channel
blocker
reduc
case
fatal
rate
although
research
necessari
develop
sftsspecif
therapi
consider
progress
achiev
area
summar
discuss
recent
advanc
antivir
drug
sftsv
keyword
sever
fever
thrombocytopenia
syndrom
sever
fever
thrombocytopenia
syndrom
viru
antivir
ribavirin
favipiravir
frontier
microbiolog
wwwfrontiersinorg
sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
infecti
diseas
caus
sft
viru
sftsv
novel
bunyaviru
classifi
genu
phleboviru
famili
bunyavirida
accord
previou
nomenclatur
intern
committe
taxonomi
virus
ictv
howev
accord
nomenclatur
ictv
sftsv
classifi
genu
banyangviru
famili
phenuivirida
renam
huaiyangshan
banyangviru
review
articl
refer
sftsv
sftsv
negativestrand
rna
viru
genom
compris
three
segment
design
larg
l
medium
small
l
segment
encod
rna
depend
rna
polymeras
rdrp
glycoprotein
precursor
gn
gc
respect
segment
encod
nucleoprotein
nonstructur
protein
rdrp
sftsv
respons
viral
replic
major
target
nucleosid
analog
use
therapeut
antivir
drug
gn
gc
present
surfac
virion
main
target
neutral
antibodi
sftsv
first
isol
patient
present
fever
thrombocytopenia
leukocytopenia
multiorgan
dysfunct
hubei
henan
provinc
central
china
yu
et
al
subsequ
viru
isol
sick
patient
japan
south
korea
indic
sftsv
endem
china
also
south
korea
japan
kim
et
al
takahashi
et
al
addit
recent
studi
report
sft
endem
vietnam
tran
et
al
xinjiang
china
zhu
et
al
indic
distribut
sftsv
southeast
asia
might
much
extens
expect
human
becom
infect
mainli
via
tickbit
close
contact
anim
cat
dog
humantohuman
transmiss
also
report
gai
et
al
niu
et
al
kida
et
al
case
fatal
rate
sft
found
vari
japan
south
korea
fatal
rate
approxim
choi
et
al
kato
et
al
although
world
health
organ
list
sft
diseas
requir
urgent
research
develop
world
health
organ
avail
effect
sft
treatment
develop
vaccin
sftsv
infect
attempt
dong
et
al
kwak
et
al
develop
specif
treatment
sft
crucial
sftsv
infect
rel
rare
affect
patient
mainli
elderli
propos
treatment
sft
includ
steroid
puls
therapi
nakamura
et
al
plasma
exchang
oh
et
al
yoo
et
al
antivir
drug
saijo
howev
effect
remain
unclear
sftsv
infect
varieti
cultur
cell
includ
vero
vero
cell
yu
et
al
sever
studi
conduct
identifi
effect
antivir
agent
sftsv
screen
compound
librari
test
agent
effect
virus
tabl
suggest
antivir
drug
may
potenti
effect
treatment
multipl
viral
infect
test
approv
drug
consid
reason
strategi
de
clercq
li
suffici
anim
model
requir
evalu
efficaci
antivir
drug
treatment
sftsv
infect
howev
adult
mice
hamster
suscept
sftsv
infect
nonhuman
primat
model
show
mild
symptom
similar
sft
human
jin
et
al
sever
immunodefici
immatur
anim
model
avail
mice
defici
interferon
receptor
ifnar
liu
et
al
tani
et
al
mice
syrian
hamster
defici
gene
encod
signal
transduc
activ
transcript
yoshikawa
et
al
found
suscept
sftsv
infect
follow
subcutan
inocul
newborn
mice
rat
suscept
sftsv
infect
inocul
intracerebr
chen
et
al
zivcec
et
al
ning
et
al
tabl
present
anim
model
use
determin
efficaci
antivir
drug
sftsv
infect
review
articl
summar
discuss
recent
advanc
made
sftsv
treatment
use
antivir
drug
ribavirin
nucleotid
analog
exert
broad
spectrum
antivir
activ
variou
virus
respiratori
syncyti
viru
influenza
measl
herpesviru
human
immunodefici
viru
lassa
viru
combin
interferon
ifn
hepat
c
viru
ribavirin
administ
oral
intraven
via
nebul
snell
propos
mechan
action
ribavirin
virus
indirect
inosin
monophosph
dehydrogenas
inhibit
immunomodulatori
effect
well
direct
interfer
rna
cap
polymeras
inhibit
lethal
mutagenesi
graci
cameron
shimojima
et
al
first
report
efficaci
ribavirin
vitro
use
three
cell
line
monkey
kidneyderiv
vero
human
hepatomaderiv
human
osteosarcomaderiv
cell
treat
ribavirin
infect
sftsv
inhibitori
concentr
ic
ribavirin
vero
cell
respect
tabl
howev
vero
cell
treat
ribavirin
day
inocul
inhibitori
effect
dramat
decreas
suggest
ribavirin
could
use
postexposur
prophylaxi
prevent
sft
also
mention
ribavirin
could
effect
part
combin
therapi
treat
sft
patient
shimojima
et
al
efficaci
ribavirin
sftsv
replic
also
observ
anoth
studi
vero
cell
infect
korean
sftsv
strain
treat
h
post
inocul
inhibitori
concentr
ic
rang
lee
et
al
tabl
despit
sever
differ
viral
strain
treatment
procedur
ribavirin
suppress
sft
replic
suggest
effect
variou
sftsv
least
h
sftsv
inocul
shimojima
et
al
investig
improv
efficaci
ribavirin
use
combin
ifn
ifn
show
dosedepend
inhibitori
effect
use
alon
ic
uml
uml
ngml
respect
ribavirin
tabl
ifn
combin
ribavirin
ic
signific
inhibitori
effect
observ
reduct
log
viral
titer
studi
suggest
combin
ribavirin
ifn
agent
function
via
differ
mechan
might
use
treat
patient
sft
ribavirin
shown
limit
protect
effect
lethal
sftsv
challeng
anim
experi
tani
et
al
tabl
chines
ministri
health
initi
approv
use
ribavirin
treat
sft
base
result
vitro
studi
ministri
health
peopl
republ
china
howev
clinic
studi
china
show
case
fatal
rate
similar
patient
receiv
ribavirin
liu
et
al
studi
includ
patient
die
receiv
ribavirin
therapi
platelet
count
increas
viral
load
decreas
comparison
receiv
therapi
furthermor
although
differ
statist
signific
unexpectedli
observ
patient
receiv
ribavirin
therapi
lower
platelet
count
anoth
studi
report
two
patient
plasma
exchang
ribavirin
treatment
initi
earli
recov
rapidli
progress
sft
oh
et
al
patient
platelet
count
began
gradual
recov
initi
ribavirin
treatment
furthermor
accord
largescal
epidemiolog
studi
china
includ
patient
laboratoryconfirm
sft
ribavirin
therapi
effect
reduc
case
fatal
rate
patient
patient
patient
viral
load
copiesml
li
et
al
howev
effect
observ
among
viral
load
copiesml
favipiravir
discov
synthes
toyama
chemic
co
ltd
exert
broad
spectrum
activ
variou
rna
virus
includ
influenza
viru
arenavirus
bunyavirus
west
nile
viru
yellow
fever
viru
footandmouth
diseas
viru
furuta
et
al
favipiravir
convert
activ
form
host
enzym
inhibit
viral
rna
polymeras
host
cell
report
indic
resist
favipiravir
vitro
delang
et
al
goldhil
et
al
shown
tabl
favipiravir
significantli
inhibit
sftsv
replic
vitro
tani
et
al
baba
et
al
vivo
tani
et
al
tani
et
al
smee
et
al
furthermor
ic
favipiravir
vero
cell
tani
et
al
lower
ribavirin
shimojima
et
al
efficaci
favipiravir
vivo
examin
use
anim
model
tabl
intraperiton
ip
administr
favipiravir
dose
mgkgday
day
complet
protect
mice
death
upon
sftsv
infect
caus
slight
reduct
weight
tani
et
al
hand
mice
treat
frontier
microbiolog
wwwfrontiersinorg
ribavirin
ip
dose
mgkgday
lost
bodi
weight
die
sftsv
infect
reduct
case
fatal
rate
favipiravirtr
mice
surviv
treatment
initi
earlier
day
post
infect
wherea
mice
treat
day
post
infect
exhibit
surviv
respect
tani
et
al
result
demonstr
favipiravir
would
potenti
effect
prophylact
use
also
treat
sftsv
infect
gener
favipiravir
oral
administr
human
oral
administr
po
favipiravir
show
similar
efficaci
ip
administr
mous
model
tani
et
al
furthermor
treatment
favipiravir
mgkgday
provid
complet
protect
lethal
sftsv
challeng
knockout
golden
syrian
hamster
model
addit
efficaci
favipiravir
practic
dosag
mgkgday
po
investig
mous
infect
model
mice
surviv
treatment
initi
later
day
post
infect
tani
et
al
hexachlorophen
yuan
et
al
screen
fdaapprov
drug
librari
contain
drug
compound
identifi
five
inhibit
sftsv
replic
concentr
includ
two
antibacteri
antifung
disinfect
hexachlorophen
triclosan
multikinas
inhibitor
treatment
advanc
solid
organ
tumor
regorafenib
small
molecul
agonist
cmannosyl
thrombopoietin
receptor
cmpl
treatment
immun
thrombocytopen
purpura
aplast
anemia
eltrombopag
antiprotozo
agent
broxyquinolin
hexachlorophen
potent
ic
rna
load
plaqu
reduct
highest
select
index
cytotox
concentr
cc
ic
lower
four
antivir
drug
identifi
tabl
furthermor
result
indic
hexachlorophen
treatment
interf
sftsv
entri
without
affect
virushost
cell
attach
cell
viru
infect
yuan
et
al
predict
hexachlorophen
would
bind
deep
hydrophob
pocket
domain
iii
sftsv
gc
glycoprotein
would
interfer
cell
membran
fusion
hexachlorophen
antibacteri
compound
common
constitu
soap
scrub
experiment
use
cholinesteras
inhibitor
hsu
et
al
report
hexachlorophen
inhibit
viral
replic
sever
acut
respiratori
syndromerel
coronaviru
vitro
inhibit
proteas
essenti
lifecycl
hsu
et
al
calcium
channel
blocker
ccb
reduc
intracellular
ca
level
wide
use
treat
variou
cardiovascular
diseas
includ
hypertens
angina
supraventricular
arrhythmia
recent
antivir
activ
ccb
ebolaviru
sakurai
et
al
marburgviru
dewald
et
al
viru
lavanya
et
al
west
nile
viru
scherbik
brinton
japanes
enceph
viru
report
screen
librari
fdaapprov
drug
identifi
ccb
benidipin
hydrochlorid
nifedipin
inhibitor
sftsv
replic
vitro
impair
viru
intern
reduc
genom
replic
postentri
phase
mechan
affect
viral
bind
fusion
bud
result
vitro
studi
suggest
treatment
benidipin
hydrochlorid
nifedipin
inhibit
sftsv
replic
reduc
viru
induc
ca
influx
antisftsv
effect
two
ccb
analyz
mice
human
mous
model
tabl
reveal
treatment
effect
reduc
viral
load
increas
platelet
count
decreas
fatal
rate
human
mous
model
notabl
nifedipin
one
wide
use
drug
treat
hypertens
atherosclerosi
china
thu
li
et
al
perform
retrospect
clinic
investig
larg
cohort
patient
sft
compris
nifedipinetr
receiv
nifedipin
admiss
hospit
nonnifedipinetr
one
receiv
nifedipin
admiss
hospit
gener
sft
patient
receiv
nifedipin
case
fatal
rate
decreas
nifedipinetr
group
compar
gener
sft
group
nonnifedipin
treat
group
contrast
ribavirin
signific
decreas
case
fatal
rate
also
observ
nifedipinetr
patient
high
viral
load
copiesml
compar
gener
sft
patient
nonnifedipinetr
patient
hematemesi
one
hemorrhag
manifest
close
relat
death
found
occur
less
frequent
nifedipinetr
group
articl
author
clearli
show
inhibitori
effect
benidipin
hydrochlorid
nifedipin
cultur
cell
anim
model
importantli
found
nifedipin
administr
enhanc
viru
clearanc
improv
clinic
recoveri
deoxycytidin
deoxycytidin
fdc
nucleosid
inhibitor
use
anticanc
drug
inhibit
variou
rna
dna
virus
vitro
borna
viru
bajramov
et
al
lassa
viru
welch
et
al
crimeancongo
hemorrhag
fever
viru
welch
et
al
influenza
viru
kumaki
et
al
herpesvirus
wohlrab
et
al
smee
et
al
shown
antivir
activ
fdc
variou
bunyavirus
la
cross
viru
mapor
viru
punta
toro
viru
rift
valley
fever
viru
san
angelo
viru
heartland
viru
sftsv
ic
fdc
sftsv
vitro
assay
tabl
valu
much
lower
ribavirin
studi
favipiravir
studi
conduct
tani
et
al
vivo
studi
use
ifnar
mice
mgkgday
treatment
fdc
protect
death
caus
sftsv
tabl
howev
mice
treat
fdc
experienc
substanti
weight
loss
sftsv
inocul
wherea
favipiravirtr
mice
display
littl
weight
loss
suggest
favipiravir
effect
fdc
control
morbid
infect
smee
et
al
also
found
treatment
mgkgday
either
fdc
favipiravir
significantli
reduc
viral
titer
serum
furthermor
slight
discrep
surviv
rate
viru
titer
mice
treat
mgkgday
fdc
mgkgday
fdc
surviv
rate
vs
treatment
respect
viru
titer
serum
mgkgdaytreat
mice
higher
mice
receiv
treatment
specul
caus
limit
sampl
size
n
caffeic
acid
ca
coffeerel
polyphenol
organ
compound
found
variou
plant
includ
coffe
bean
singl
cup
coffe
contain
mg
chlorogen
acid
ester
caffeic
acid
clifford
exert
varieti
biolog
effect
includ
suppress
cancer
cell
tang
et
al
et
al
antivir
properti
wang
et
al
utsunomiya
et
al
ding
et
al
langland
et
al
ogawa
et
al
show
ca
dosedepend
inhibit
sftsv
replic
vitro
assay
use
cell
highli
permiss
deriv
human
hepatoma
cell
ic
ca
sftsv
cc
mm
tabl
interestingli
pretreat
sftsv
ca
prior
inocul
effect
reduc
viru
copi
number
supernat
infect
cell
h
post
infect
inhibitori
effect
significantli
reduc
cell
treat
ca
sftsv
inocul
thu
author
specul
ca
mainli
act
viral
particl
influenc
earli
stage
sftsv
infect
although
could
act
host
cell
inhibit
viral
genom
replic
amodiaquin
novel
compound
routin
prescrib
antimalari
drug
report
show
antivir
effect
ebolaviru
gignoux
et
al
sakurai
et
al
dengu
viru
boonyasuppayakorn
et
al
zika
viru
balasubramanian
et
al
mechan
inhibitori
activ
amodiaquin
malaria
virus
remain
unclear
baba
et
al
investig
effect
amodiaquin
halogen
molecul
fluorin
bromin
iodin
replic
sftsv
vitro
deriv
also
display
antisftsv
activ
ic
fluorin
bromin
iodin
respect
tabl
among
compound
test
amodiaquin
identifi
select
inhibitor
sftsv
replic
cc
ic
amodiaquin
respect
ic
amodiaquin
lower
ribavirin
favipiravir
member
type
ii
ifn
stimul
macrophag
dendrit
cell
induc
direct
antimicrobi
activ
regul
antigen
process
present
pathway
initi
thought
activ
cell
activ
natur
killer
cell
relev
sourc
howev
macrophag
dendrit
cell
also
stimul
produc
vitro
certain
condit
kiderlen
directli
stimul
express
potenti
antivir
ifnstimul
protein
signal
play
import
role
viral
infect
ning
et
al
use
enzymelink
immunosorb
assay
demonstr
sftsv
infect
caus
substanti
product
serum
patient
sft
turn
exhibit
robust
antisftsv
activ
cultur
cell
thereaft
evalu
efficaci
antisftsv
drug
vivo
suckl
mous
model
show
treatment
prior
sftsv
infect
significantli
reduc
mortal
protect
anim
death
wherea
untreat
mice
die
within
day
sftsv
challeng
administr
post
sftsv
infect
mice
die
viru
sinc
consider
number
studi
regard
epidemiolog
virolog
characterist
conduct
ribavirin
one
broadspectrum
antivir
drug
beaucourt
vignuzzi
recommend
patient
sft
china
use
treat
consider
number
patient
ministri
health
peopl
republ
china
vitro
vivo
studi
ribavirin
shimojima
et
al
shimojima
et
al
tani
et
al
lee
et
al
show
consider
effect
result
clinic
studi
conduct
liu
et
al
show
ribavirin
reduc
fatal
rate
patient
sft
discourag
us
consid
ribavirin
treatment
treat
patient
sft
howev
li
et
al
report
ribavirin
effect
earlystag
patient
low
viral
titer
pretreat
expos
individu
nevertheless
case
ribavirin
administr
patient
intens
monitor
possibl
advers
event
induc
ribavirin
anemia
hyperamylasemia
lu
et
al
favipiravir
exhibit
higher
effect
ribavirin
vitro
vivo
studi
tani
et
al
tani
et
al
meanwhil
favipiravir
remain
effect
use
follow
sftsv
infect
anim
model
tani
et
al
tani
et
al
indic
potenti
effect
drug
treat
sft
patient
current
clinic
trial
underway
evalu
efficaci
favipiravir
treat
patient
sft
japan
cyranoski
spengler
et
al
besid
would
desir
use
intraven
administr
sft
patient
sever
symptom
could
difficulti
take
drug
oral
hexachlorophen
antibacteri
compound
found
effect
sftsv
vitro
screen
use
fdaapprov
drug
librari
yuan
et
al
hexachlorophen
caus
acut
subacut
neurotox
laboratori
anim
human
kimbrough
ramu
et
al
vitro
vivo
studi
must
conduct
ccb
use
control
cardiovascular
diseas
demonstr
signific
effect
sftsv
replic
vitro
vivo
notabl
retrospect
conduct
clinic
studi
suggest
nifedipin
remark
reduc
case
fatal
rate
sft
patient
although
nifedipin
administr
consist
patient
cardiac
diseas
find
valuabl
develop
potenti
ccbbase
therapeut
sft
consid
efficaci
nifedipin
treat
patient
sft
evalu
prospect
manner
clinic
use
care
consider
risktobenefit
valu
patient
would
requir
overdos
ccb
highrisk
side
effect
edema
liver
damag
death
dose
use
vivo
mous
studi
mgkgday
extrem
higher
dose
gener
use
human
mgkgday
still
find
indic
potenti
therapeut
effect
ccb
treatment
patient
sft
fdc
consid
viabl
candid
therapeut
agent
sft
although
fdc
effect
favipiravir
vitro
vivo
efficaci
less
favipiravir
smee
et
al
administr
protocol
fdc
consid
futur
studi
ca
show
inhibitori
effect
sftsv
vitro
littl
known
mechan
action
consid
ca
interact
viral
particl
show
inhibitori
effect
ogawa
et
al
limit
report
regard
antivir
effect
ca
chlorogen
acid
vivo
wang
et
al
ding
et
al
studi
need
baba
et
al
show
amodiaquin
halogen
molecul
effect
inhibit
propag
sftsv
vitro
amodiaquin
wide
use
antimalari
drug
administ
low
cost
efficaci
amodiaquin
vivo
evalu
antisftsv
efficaci
vitro
vivo
ning
et
al
report
fdaapprov
drug
suggest
candid
antivir
drug
sftsv
alon
combin
drug
shimojima
et
al
efficaci
antibodybas
treatment
studi
sft
diseas
gener
antibodi
play
critic
role
treat
wide
varieti
viral
diseas
acquir
immunodefici
syndrom
ferrari
et
al
diseas
caus
ebola
viru
mendoza
et
al
influenza
nachbagau
krammer
antibodi
drug
neutral
virus
bind
virion
enhanc
antigen
uptak
cytotox
cell
make
highli
specif
target
viru
report
antiserum
patient
recov
sft
complet
protect
mice
lethal
infect
sftsv
shimada
et
al
also
shown
antibodi
sftsv
gn
protein
significantli
reduc
fatal
rate
mice
infect
sftsv
even
treatment
initi
day
post
inocul
report
suggest
antibodi
alon
combin
antivir
drug
could
use
treat
patient
sft
two
studi
develop
vaccin
sftsv
infect
dong
et
al
kwak
et
al
recombin
vesicular
stomat
viru
express
sftsv
antigen
complet
protect
mice
sftsv
infect
dong
et
al
dna
vaccin
express
antigen
sftsv
elicit
neutral
antibodi
respons
sftsvspecif
cell
respons
protect
agedferret
lethal
sftsv
infect
kwak
et
al
safe
effect
vaccin
sft
develop
mention
drug
inhibitori
effect
sftsv
replic
combin
therapi
drug
differ
mechan
action
consid
although
consid
antivir
drug
sft
would
administr
presymptomat
expos
individu
main
target
drug
certainli
patient
suggest
symptom
sft
sftsv
circul
mammal
tick
southeast
asia
indic
escap
risk
infect
sftsv
sft
classifi
diseas
categori
viral
hemorrhag
fever
high
case
fatal
rate
recent
case
sft
report
wherein
patient
infect
sftsv
cat
might
infect
sftsv
tick
kida
et
al
therefor
hope
specif
treatment
antivir
agent
develop
approv
patient
sft
earli
possibl
ms
mti
conceptu
design
studi
mti
collect
assembl
data
draft
manuscript
ms
critic
revis
manuscript
part
review
articl
obtain
studi
financi
support
ministri
health
labour
welfar
grant
number
japan
agenc
medic
research
develop
ame
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
